Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1078 participants.

Also called NCT00826059

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,078 participants (enrolled count) (from the registry)
Sponsor
BrainsGate (from the registry)
Registry
  • NCT NCT00826059
Other papers using this trial's data
  • An injectable implant to stimulate the sphenopalatine ganglion for treatment of acute ischaemic stroke up to 24 h from onset (ImpACT-24B): an international, randomised, double-blind, sham-controlled, pivotal trial Lancet (London, England), 2019-07-20 DOI, PubMed 31133406

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Hong Kong SAR China, Israel, Italy, North Macedonia, Poland, Portugal, Serbia, Slovakia, Spain, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT00826059. Randomized; triple masking; primary purpose treatment. Start 2011-06 (actual); primary completion 2018-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window
Acronym
ImpACT-24B
Intervention (Device)
Active Sphenopalatine Ganglion (SPG) Stimulation
Intervention (Device)
Sham Sphenopalatine Ganglion (SPG) Stimulation
Lead sponsor
BrainsGate (class: industry)

Record details

Record id
cardio:ct-nct00826059
Content hash
b06448055d1bb9d04be7d119995694304624a9962f46cdc45e09bc946693fe0a